Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom.

ABSTRACT:

Objectives

We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom.

Methods

Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first-time rVWF for the prevention/treatment of surgery-related bleeds, or the on-demand treatment of spontaneous/traumatic bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD-related HCRU data associated with the prevention/treatment of surgery-related bleeds were collected at first (index) event, for 12 months pre-index and 3-12 months post-index.

Results

Twenty patients (55.0% female, 90.0% White/Caucasian, mean age

SUBMITTER: Laffan M 

PROVIDER: S-EPMC12673352 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature